tabelecleucel,ESG401,Posoleucel
sorrento therapeutics,atara biotherapeutics,NexImmune, AlloVir pharma,Synlogic,Pivotal Therapeutics
['solid tumor', 'tab-cel', 'aml,(-streamline),(-seamless),(-kamloops),(-latamleaders)', 'aml,(-streamline),(-seamless),(-kamloops),(-dreamlike)', '$atra', '$srne', 'atara ']
$srne: esg401 shows solid tumor success.
$sybx $pvttf: synlogic starts global phase 3 study.
$atra: atara presents tab-cel data at asco.
$alvr: allovir trial: posoleucel treats bk infection.
$nexi: neximmune's aml treatment shows promise.
BioPharma/Biotech Intel.  Daily $XBI $XPH Market Movers

Database: https://t.co/IBOqbSoYuc
Clinical trial tools: https://t.co/A77u9Q84Dc  http://globalclinicalt